Myriad Genetics, has entered into a collaboration with GSK to broaden access to homologous recombination deficiency (HRD) diagnostic testing for high-grade serous ovarian cancer (HGSOC) patients. Through this partnership, a sponsored testing program employing Myriad’s MyChoice HRD Plus and MyChoice CDx Plus Tests is being introduced across several countries, including Argentina, Brazil, and the United Arab Emirates. These tests serve a critical role in identifying HRD status, equipping clinicians with valuable information to make personalized treatment decisions for individuals battling ovarian cancer.
The collaboration between Myriad Genetics and GSK aims to address the pressing need for accessible testing solutions in underserved markets, ensuring that patients, regardless of their geographic location, can benefit from advanced genetic insights. Patrick Burke, the Executive Vice President of Strategy and Innovation at Myriad Genetics, highlighted the significance of this collaboration in advancing healthcare equity and extending the reach of diagnostic solutions to support tailored patient care based on individual genomic profiles.
Myriad’s MyChoice Test stands out as the most comprehensive tumor test available, offering a detailed analysis of genomic alterations, including in genes such as BRCA1 and BRCA2, alongside the Genomic Instability Score (GIS) status determined through a proprietary algorithm. This depth of analysis enables healthcare professionals to identify patients who are more likely to respond to treatment with targeted therapies, thereby improving treatment outcomes and patient quality of life.